InvestWiserOncoinvent ASA
ONCIN · Oslo Børs · Healthcare
82.80NOK
−0.5%last day
Price as of 2 October 2026
Performance
1 month
−6.5%
1 year
+5.4%
3 years, per year
−50.5%
5 years, per year
−76.5%
Largest fall, 3 years
−99.9%
Below the peak now
−100.0%
Volatility, 1 year
114.8%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
4.7
Dividend yield
0.0%
Return on equity
−37.0%
Net margin
–
Market value
38 m USD
Quality, value and trend
Where Oncoinvent stands against every Nordic stock today. 100 is best.
74
Profitability and a sound balance sheet over time. Better than 74% of Nordic stocks.
3
The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.
94
The price development over the past year. Better than 94% of Nordic stocks.
60
Quality, value and trend together. Better than 60% of Nordic stocks.
About Oncoinvent
Oncoinvent ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 42 employees.
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis